CCL2 and glioblastoma: It is hard to define molecular subtype of GBM cell line, but our work indicated that treatment of CCL2 and LIF altered gene expression profiles in GBM cells, which significantly enriched signature genes of mesenchymal subtype, but failed to enrich signature genes of other molecular subtypes.